Danaher (DHR)
(Delayed Data from NYSE)
$275.19 USD
+3.54 (1.30%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $273.89 -1.30 (-0.47%) 6:14 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$275.19 USD
+3.54 (1.30%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $273.89 -1.30 (-0.47%) 6:14 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Danaher (DHR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Surprise Coming for Danaher (DHR) This Earnings Season?
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Danaher (DHR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Danaher (DHR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher Shares Gain 26% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Danaher (DHR), with 26% growth in shares in the past three months, benefits from healthy demand for its products and synergistic benefits from acquired assets despite the pandemic-led woes.
When Does Market Timing Actually Work? - July 02, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Griffon to Pay Down Debts From Proceeds of Notes Offering
by Zacks Equity Research
Griffon (GFF) closes the offering of $150 million worth of senior notes. The proceeds will be used for redeeming notes due to expire in 2022, and pay for fees and expenses.
3M's (MMM) Sales Fall Y/Y in May on Lower Business Days
by Zacks Equity Research
3M's (MMM) weak sales performance in May gets affected by two lower business days. Also, the pandemic-induced uncertainties play spoilsport for segments and end-market businesses.
Yes, You Can Time the Market. Find out How - June 10, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Griffon (GFF) Prices $150M Worth of Senior Notes Offering
by Zacks Equity Research
Griffon (GFF) prices $150 million worth of senior notes offering. The proceeds will likely be used for redeeming notes due to expire in 2022, and pay for fees and expenses.
Danaher's (DHR) Product Offerings to Aid Amid Pandemic Scares
by Zacks Equity Research
Danaher's (DHR) risks from pandemic-related uncertainties are evident from weak sales projections for the second quarter. Demand for acute care diagnostics' related products might aid results.
Why Is Danaher (DHR) Up 3.3% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Donaldson's (DCI) Prospects Bleak on Coronavirus Scares
by Zacks Equity Research
Donaldson (DCI) suffers from the adverse impacts of the pandemic and keeps the projections suspended for fiscal 2020. Forex woes and high leverage are also concerning.
3M's (MMM) Solid Product Portfolio to Aid Amid Pandemic
by Zacks Equity Research
3M (MMM) faces risks from the pandemic-related uncertainties, evident from a sales decline in April. However, cost-reduction measures and huge demand for respirators will likely support results in the second quarter.
General Electric to Divest Lighting Business, Shares Rise
by Zacks Equity Research
General Electric's (GE) divestment of the lighting business to Savant Systems will help it progress on its efforts to transform into an industrial company.
Diversified Operations Industry Outlook Bleak on Coronavirus Woes
by Payal Jalan
The pandemic's adverse impacts on multiple end markets, especially commercial aerospace, general industrial and others, hurt the diversified operations industry's prospects. However, pandemic-induced demand for many products might aid.
Danaher's Stock Offering Proceeds to Fund Corporate Needs
by Zacks Equity Research
Danaher (DHR) completes the offering of common and convertible preferred shares. It intends on using the funds raised to pay for its corporate needs.
Danaher (DHR) Beats Q1 Earnings Estimates, Provides Bleak View
by Zacks Equity Research
Danaher's (DHR) Q1 results reflect healthy growth in organic sales and the impacts of forex woes. Core sales in Q2 are expected to reflect the pandemic woes and gains from Cytiva.
Danaher (DHR) Q1 Earnings Top Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 5.00% and -0.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Danaher (DHR) This Earnings Season?
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Danaher (DHR) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Danaher's (DHR) Q1 results are expected to reflect healthy segmental growth. However, adverse impacts of the coronavirus outbreak on demand are anticipated to have ailed.
Timing the Market, Is it Possible? - May 04, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Danaher (DHR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Danaher (DHR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
General Electric (GE) Q1 Earnings Lag Estimates, View Gloomy
by Zacks Equity Research
General Electric's (GE) first-quarter 2020 earnings reflect the adverse impacts of the coronavirus outbreak. Persistence of the headwinds is likely to impact second-quarter results as well.